Low-grade spiradenocarcinoma is a rare skin tumor, with fewer than six reported cases, arising in the context of CYLD cutaneous syndrome (CCS; syn: Brooke-Spiegler syndrome [BSS]). We report two independent cases of spiradenocarcinoma arising in a 50-year-old man with CCS.
| INTRODUCTION
Low-grade spiradenocarcinoma is a rare skin tumor that may arise in CYLD cutaneous syndrome (CCS). Recently, CYLD loss as a genetic driver in inherited cylindromas and spiradenomas, associated with increased MYB signaling, has been recognized in CCS. 1 In contrast, sporadic cutaneous cylindromas recurrently harbor MYB-NFIB fusion transcripts 2 that result in MYB overexpression. The convergence on MYB signaling in inherited and sporadic tumors suggests that the biology of sporadic spiradenocarcinoma may be informed by the study of CCS patients. We report a case of two spiradenocarcinomas arising in a 50-year-old man with CCS. The histologic features in our case corresponded to the salivary gland type basal cell adenocarcinoma-like pattern, low grade (BCAC-LG), a type previously recognized as predominating in CCS. Recognition of BCAC-LG spiradenocarcinoma can be difficult in routine practice as the features can be subtle and easily missed, especially in those cases where the transition from benign to malignant tumor is gradual. We examined the expression pattern of p63 and smooth muscle actin (SMA) in our two cases of BCAC-LG spiradenocarcinoma and suggest that these immunohistochemical markers may aid in the distinction of BCAC-LG spiradenocarcinoma from spiradenoma in CCS.
| CASE REPORT
A 50-year-old male presented with a rapidly enlarging lesion on his back. He had multiple skin lesions affecting most of his upper body, arms, and face ( Figure 1A ). The patient had first noticed skin tumors around the age of 18 years, and had multiple lesions removed, which were confirmed as cylindromas and spiradenomas. reported in CCS, showed a relatively indolent course, characterized by local recurrence. 6 We add to the six reported cases of BCAC-LG discriminating malignant components due to variability of expression across the cases assessed. p63 expression has been described in a single case of sporadic BCAC-LG spiradenocarcinoma. 9 The authors showed a difference in staining between benign and malignant components, compatible with our findings. We provide additional data on the pattern and intensity of p63 and SMA expression in CCS, suggesting that these markers may aid the histopathologic recognition of BCAC-LG spiradenocarcinoma. Taken together with the morphological features seen in BCAC-LG type spiradenocarcinoma, these immunohistochemical markers may aid diagnosis; however, further studies in a large series are important to confirm this impression.
In summary, we present a patient with two cases of spiradenocarcinoma, arising in a setting of CCS. Subclassification of subtypes appears to be important, as it has been suggested that the histology influences prognosis. Our follow-up data is supportive of the relative indolent clinical course BCAC-LG type spiradenocarcinoma in CCS has been noted to have, and this may influence the clinical management of these rare patients.
